Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.
Novo Nordisk's decision to free up resources for R&D investment means 1,300 lay-offs across the company by the end of the year. The Danish group is meanwhile stockpiling medicines and bolstering its supply chain outside the UK in case of a 'no deal' hard Brexit, its CEO says.
Latest From Brexit
Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.
The UK government has been working on plans to ensure medical devices, among other goods, can still "flow into the country, and won't be delayed by additional controls and checks."
EU Regulatory Roundup, November 2018: 'Implant Files' Dominate, While Brexit/New Reg Issues Rumble On
The medtech sector was already quite overwhelmed with the new EU regulations and Brexit uncertainties. Now add into the mix the impact of the global journalistic Implant Files investigation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.